Chronotherapy in Acute Multiple Sclerosis (MS) Attack

• Status: Terminated
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The Immunological system is showing a diurnal rhythmicity. The Mediators that enhances inflammation are at highest level during the night. At the same time the endogenous production of cortisol is at its lowest. We want to study if there is a better effect of treatment with Methylprednisolone for acute MS-attacks if given at nighttime. The effect will be measured in relation to neurological deficits and function with Kurtzkes Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC). We want to see if the mean improvement in EDSS is greater in the group receiving treatment at night opposed to the group that get treatment during the daytime.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sykehuset Innlandet HF
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Relapsing remitting MS

• EDSS-score before the actual attack < 6.0

• Acute MS-attack with indication for treatment with steroids

• Symptoms >24 hours < 4 weeks

• Age 18 years or older

Exclusion Criteria:

• Prior enrollment in this study

• Ongoing serious infection that is a contraindication for treatment with steroids

• Pregnancy

• Medical situations (prior acute diseases) where treatment with intravenous steroids over short period of time is contraindicated or not favorable.

• Enhanced cognitive dysfunction

• Treatment with p.o or i.v steroids within 3 weeks prior to date of inclusion